Related Experiment Video

Updated: Dec 30, 2025

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.1K

Antihypertensive therapy and sudden cardiac death, should we expect the unexpected?

Elias Sanidas1, Konstantinos Malliaras2, Dimitrios Papadopoulos2

  • 1Hypertension Excellence Centre-ESH, Department of Cardiology, LAIKO General Hospital, Athens, Greece. easanidas@yahoo.gr.

Journal of Human Hypertension
|January 16, 2020
PubMed

Insights

Hypertension and sudden cardiac death are major health issues. While blood pressure drugs reduce heart attacks, they may not prevent sudden cardiac death, warranting further investigation.

Area of Science:

  • Cardiology
  • Public Health
  • Pharmacology

Background:

  • Hypertension (HTN) and sudden cardiac death (SCD) are significant global health concerns.
  • Hypertension-induced left ventricular hypertrophy (LVH) is an independent risk factor for SCD.
  • The relationship between antihypertensive treatments and SCD risk requires further exploration.

Purpose of the Study:

  • To review the links between HTN, LVH, and SCD.
  • To examine the potential association between antihypertensive pharmacotherapy and SCD risk.

Main Methods:

  • Literature review of existing studies on hypertension, LVH, SCD, and antihypertensive medications.
  • Analysis of data regarding the efficacy of various antihypertensive drug classes in preventing SCD.

Main Results:

  • Antihypertensive pharmacotherapy effectively reduces overall cardiovascular mortality.
  • Available data suggest that while some antihypertensive drugs (e.g., thiazide diuretics) reduce myocardial infarction, they do not offer protection against SCD.
  • The protective effect of antihypertensive therapy against SCD remains under-investigated.

Conclusions:

  • HTN and LVH are established risk factors for SCD.
  • Current antihypertensive medications may not adequately address the risk of SCD, despite their benefits in reducing overall cardiovascular mortality.
  • Further research is crucial to understand and mitigate the risk of SCD in hypertensive patients.

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.8K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
844
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
310
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
256
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
203
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
697
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.3K